Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration

References

• Jenning V, Schäfer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release 2000;66:115–26.
   PubMed Web of Science ®Google Scholar
• Santos MC, Mehnert W, Schäfer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 2000;196:165–7.
   PubMed Web of Science ®Google Scholar
• Jenning V, Gohla S. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul 2001;18:149–58.
   PubMed Web of Science ®Google Scholar
• Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;27:71–7.
   Google Scholar
• Surajit D, Wai Kiong N, Reginald BHT. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012;47:139–51.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mehnert W, Lucks JS, et al. Solid lipid nanoparticles (SLN) – an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995;41:62–9.
   Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242:121–8.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54:S131–55.
   PubMed Web of Science ®Google Scholar
• Freitas C, Müller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999;47:125–32.
   PubMed Web of Science ®Google Scholar
• Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011;12:62–76.
   PubMed Web of Science ®Google Scholar
• Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1997;48:223–36.
   Web of Science ®Google Scholar
• Radtke M, Souto EB, Müller RH. Nanostructured lipid carriers: a novel generation of solid lipid drug carriers. Pharm Technol Eur 2005;17:45–50.
   Google Scholar
• Han F, Yin R, Che X, et al. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. Int J Pharm 2012;439:349–57.
   PubMed Web of Science ®Google Scholar
• Song A, Su Z, Li S, Han F. Nanostructured lipid carriers-based flurbiprofen gel after topical administration: acute skin irritation, pharmacodynamics, and percutaneous absorption mechanism. Drug Dev Ind Pharm 2015;41:1488–92.
   PubMed Web of Science ®Google Scholar
• Kovacevic A, Savic S, Vuleta G, et al. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm 2011;406:163–72.
   PubMed Web of Science ®Google Scholar
• Souza LG, Silva EJ, Martins AL, et al. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm 2011;79:189–96.
   PubMed Web of Science ®Google Scholar
• Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 2011;415:232–43.
   PubMed Web of Science ®Google Scholar
• Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 2010;74:474–82.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Lippacher A, Müller RH. Investigations on the occlusive properties of solid lipid nanoparticles (SLNTM). J Cosmet Sci 2001;52:313–23.
   PubMed Web of Science ®Google Scholar
• Han F, Li S, Yin R, et al. Investigation of nanostructured lipid carriers for transdermal delivery of flurbiprofen. Drug Dev Ind Pharm 2008;34:453–58.
   PubMed Web of Science ®Google Scholar
• de Vringer T. Topical preparation containing a suspension of solid lipid particles. European Patent No. 91200664; 1992.
   Google Scholar
• Netzlaff F, Kostka KH, Lehr CM, Schaefer UF. TEWL measurements as a routine method for evaluating the integrity of epidermis sheets in static Franz type diffusion cells in vitro. Limitations shown by transport data testing. Eur J Pharm Biopharm 2006;63:44–50.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul 1999;16:205–13.
   PubMed Web of Science ®Google Scholar
• Westesen W, Siekmann B, Koch M. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 1993;93:189–99.
   Web of Science ®Google Scholar
• Bunjes H, Westesen K, Koch M. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm 1996;129:159–73.
   Web of Science ®Google Scholar
• Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005;22:501–10.
   PubMed Web of Science ®Google Scholar
• Souto EB, Müller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 2006;23:377–88.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257–72.
   PubMed Web of Science ®Google Scholar